By Anne-Katrine Boström | Published 30 June 2020
For many people, cutting consumption of plastic has become the norm, just as recycling in general is now part of day-to-day life. But what if your life depends on a plastic product which has no obvious second life?
For people living with diabetes, their insulin pen is an essential daily companion. But even if an insulin pen consists of around 77% plastic, it cannot be thrown into the plastic recycling bin along with empty juice bottles and food packaging. Current guidance varies from country to country, but often used insulin pens end up in general household waste, which according to Dorethe Nielsen, vice president of Environmental Strategy at Novo Nordisk, is far from an optimal solution.
“Every year we produce and distribute more than 550 million pen devices worldwide, and as this number grows, it puts us at the forefront of one of the world’s biggest environmental challenges: plastic waste,” she explains.
“Even though we strive to use as environmentally friendly materials as possible, it’s still not an optimal use of resources if used insulin pens end up in landfills. That’s why we’re working to find a better and more circular solution – one that allows our devices to have a second life.”
An insulin pen is made from several components and is – for obvious
reasons – not designed to be easily disassembled once it has rolled
off the production line.
In order to recycle the plastic parts, Novo Nordisk first needed to find a way of automatically sorting the pen’s many components.
For all of this to work, one important link in the chain is still missing. An effective way of collecting used insulin pens from patients – a so-called ‘take-back’ programme – still does not exist in most countries.
“We need to come up with an easy way of collecting used pens from the users. This might sound like an easy task, but it is really something that has proven to be quite a challenge – especially on a global scale,” Dorethe says.
Dorethe is, however, expecting Novo Nordisk to launch a take-back pilot in some countries during the next couple of years. At the same time, her hope is that in future this challenge will be one that the pharmaceutical industry can unite on.
“My hope is that we can solve this together as an industry,” she says. “This is a challenge which is best approached by all of us finding a single, scalable solution, making it easy for our patients and us to take better care of the environment.”
Dorethe underlines, that the take-back pilot is not the only way, in
which we work to reuse or recycle plastic.
“We have a clear ambition to become a fully circular company, and therefore our commitment to playing our part in solving the world’s plastic challenge does not start and stop with insulin pens,” she says.
Dorethe explains that different kinds of plastic calls for different approaches.
“In 2019, we banned all single-used plastic not used for specific and relevant purposes within our R&D organisation or in production,” she says.
“But within production we also have another type of high-quality plastic waste which could easily be given a new life in all sorts of products. Since early 2000 we have been heavily invested in making sure that this happens wherever possible.”
According to Dorethe, this work is starting to bear fruit and our global production now recycles more than 90% of its waste.
“For a long time, we have been collecting plastic waste from our production, making sure that it is reused or recycled,” she says.
“But in the recent years we have seen a change in society towards a more sustainable mindset, which has allowed us to make demands on who we provide to, and that our plastic is used for sustainable products.”
“I think these are really exciting times, where we see a lot of companies and organisations coming together in finding solutions to problems that should be top of mind for all of us – how we take better care of our environment and create a more circular world.”
Our CEO, Lars Fruergaard Jørgensen, believes that now, more than ever, the world must step up its response to the rise in diabetes.
In a series of intimate portraits, photographer Abbie Trayler-Smith puts a lens on the stories and struggles of people living with obesity.
At Novo Nordisk, we’re working hard to find new therapies that can delay, prevent and even cure type 1 diabetes.
Explore features and points of view from Novo Nordisk
and the society we serve.
ZERO environmental impact
Our ambition is bold and simple: to have zero environmental impact. Recycling plastic from our pens is part of that ambission.